Cost-effectiveness of left ventricular assist devices (LVADs) for patients with advanced heart failure: Analysis of the British NHS bridge to transplant (BTT) program

被引:43
作者
Clarke, Aileen [1 ]
Pulikottil-Jacob, Ruth [1 ]
Connock, Martin [1 ]
Suri, Gaurav [1 ]
Kandala, Ngianga-Bakwin [1 ]
Maheswaran, Hendramoorthy [1 ]
Banner, Nicholas R. [2 ]
Sutcliffe, Paul [1 ]
机构
[1] Univ Warwick, Warwick Med Sch, Div Hlth Sci, Coventry CV4 7AL, W Midlands, England
[2] Univ London Imperial Coll Sci Technol & Med, Natl Heart Lung Inst, London, England
关键词
Left ventricular assist device; Heart failure; Comparative cost-effectiveness; UNITED-KINGDOM; DESTINATION;
D O I
10.1016/j.ijcard.2013.12.015
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background: A previous cost-effectiveness analysis showed that bridge to transplant (BTT) with early design left ventricular assist devices (LVADs) for advanced heart failure was more expensive than medical management while appearing less beneficial. Older LVADs were pulsatile, but current second and third generation LVADs are continuous flow pumps. This study aimed to estimate comparative cost-effectiveness of BTT with durable implantable continuous flow LVADs compared to medical management in the British NHS. Methods and results: A semi-Markov multi-state economic modelwas built using NHS costs data and patient data in the British NHS Blood and Transplant Database (BTDB). Quality-adjusted life years (QALYs) and incremental costs per QALY were calculated for patients receiving LVADs compared to those receiving inotrope supported medical management. LVADs cost 80,569 ($ 127,887) at 2011 prices and delivered greater benefit than medical management. The estimated probabilistic incremental cost-effectiveness ratio (ICER) was 53,527 pound ($ 84,963)/ QALY (95% CI: 31,802- pound 94,853; pound $ 50,479-$ 150,560) (over a lifetime horizon). Estimateswere sensitive to choice of comparator population, relative likelihood of receiving a heart transplant, time to transplant, and LVAD costs. Reducing the device cost by 15% decreased the ICER to 50,106 pound ($ 79,533)/QALY. Conclusions: Durable implantable continuous flow LVADs deliver greater benefits at higher costs than medical management in Britain. At the current UK threshold of 20,000 pound to 30,000 pound/QALY LVADs are not cost effective but the ICER now begins to approach that of an intervention for end of life care recently recommended by the British NHS. Cost-effectiveness estimates are hampered by the lack of randomized trials. (C) 2013 The Authors. Published by Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:338 / 345
页数:8
相关论文
共 26 条
[1]
Aaronson KD, 2003, ANN THORAC SURG S35, V75
[2]
[Anonymous], GUID METH TECHN APPR
[3]
[Anonymous], 2006, Decision modelling for health economic evaluation
[4]
[Anonymous], UN COSTS HLTH SOC CA
[5]
Clegg AJ, 2005, HEALTH TECHNOL ASSES, V9, P1
[6]
Clinical and cost-effectiveness of left ventricular assist devices as a bridge to heart transplantation for people with end-stage heart failure: a systematic review and economic evaluation [J].
Clegg, Andrew J. ;
Scott, David A. ;
Loveman, Emma ;
Colquitt, Jill L. ;
Royle, Pam ;
Bryant, Jackie .
EUROPEAN HEART JOURNAL, 2006, 27 (24) :2929-2938
[7]
A menu without prices [J].
Garber, Alan M. .
ANNALS OF INTERNAL MEDICINE, 2008, 148 (12) :964-966
[8]
Utility Estimates for Decision-Analytic Modeling in Chronic Heart Failure-Health States Based on New York Heart Association Classes and Number of Rehospitalizations [J].
Goehler, Alexander ;
Geisler, Benjamin P. ;
Manne, Jennifer M. ;
Kosiborod, Mikhail ;
Zhang, Zefeng ;
Weintraub, William S. ;
Spertus, John A. ;
Gazelle, G. Scott ;
Siebert, Uwe ;
Cohen, David J. .
VALUE IN HEALTH, 2009, 12 (01) :185-187
[9]
The Seattle heart failure model - Prediction of survival in heart failure [J].
Levy, WC ;
Mozaffarian, D ;
Linker, DT ;
Sutradhar, SC ;
Anker, SD ;
Cropp, AB ;
Anand, I ;
Maggioni, A ;
Burton, P ;
Sullivan, MD ;
Pitt, B ;
Poole-Wilson, PA ;
Mann, DL ;
Packer, M .
CIRCULATION, 2006, 113 (11) :1424-1433
[10]
MacGowan G, 2011, BMJ-BRIT MED J, V342